一个转移性癌症表达生成器 (MetGen):一个生成对比的学习框架,用于转移性癌症的生成
Zhentao Liu1,2, Yu-Chiao Chiu3,4, Yidong Chen5,6
1Department of Electrical and Computer, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Cancers
|May 11, 2024
概括
MetGen是一款新型深度学习工具,从原发性瘤和正常组织中生成合成转移性癌症数据. 这种方法有助于理解转移并识别潜在的治疗点,克服转录组数据的局限性.
科学领域:
- 在瘤学瘤学.
- 生物信息学是一种生物信息学.
- 计算生物学 计算生物学
背景情况:
- 转移是癌症死亡的主要原因,但获得足够的转录组数据进行研究仍然具有挑战性.
- RNA测序 (RNA-seq) 对于理解转移性癌症至关重要,但数据稀缺性阻碍了进展.
研究的目的:
- 介绍MetGen,一个基于深度学习的生成对比学习工具.
- 使用原发性癌症和正常组织数据生成合成转移性癌症表达特征.
- 为了应对转移性癌症研究中有限的转录组数据的挑战.
主要方法:
- 开发了MetGen,这是一种使用深度学习模型的生成对比学习工具.
- 在初级癌症和正常组织表达数据上训练MetGen,以生成合成转移样本.
- 通过癌症/组织分类和转移性亚型预测评估MetGen的性能.
主要成果:
- MetGen成功地生成了与实际转移性癌症数据可比的合成样本.
- 实现了高分类性能率:癌症类型为99.8 ± 0.2%,组织类型为95.0 ± 2.3%.
- 生成的样本在转移性亚型分类中显示了97.6%的预测能力,超过了像变异自编码器这样的传统模型.
结论:
- MetGen有效地为转移性癌症生成高质量的合成转录基因数据.
- 该工具确定了相关的生物特征,包括免疫反应和转移过程,提高了对转移性癌症生物学的理解.
- MetGen为识别转移性癌症治疗中的新型治疗点提供了一种有前途的方法.
相关概念视频
Mouse Models of Cancer Study
5.5K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345


